Alva Review-Courier -

Company to pay $35M for falsely marketing cholesterol drug

 

September 22, 2017



BOSTON (AP) — A Massachusetts drug company has agreed to pay more than $35 million to resolve criminal and civil charges that it falsely marketed a cholesterol medication.

The U.S. attorney's office in Boston said Friday that Aegerion Pharmaceuticals has agreed to plead guilty to two misdemeanor counts of violating federal law when it sold and promoted the drug Juxtapid as a general treatment for high cholesterol.

Federal regulators had approved the drug only for use in patients with a rare genetic disease that causes extremely high cholesterol. The drug may cause serious liver and stomac...



For access to this article please sign in or subscribe.

 

Reader Comments(0)

 
 

Our Family of Publications Includes:

Powered by ROAR Online Publication Software from Lions Light Corporation
© Copyright 2021